IBI343 Combined With Chemotherapy as Neoadjuvant Therapy in Borderline Resectable Pancreatic Cancer
NCT07415525
·
clinicaltrials.gov ↗
PHASE2
Phase
NOT_YET_RECRUITING
Status
40
Enrollment
OTHER
Sponsor class
Conditions
Pancreatic Cancer
Borderline Resectable Pancreatic Adenocarcinoma
Interventions
DRUG:
IBI343
Sponsor
Zhejiang University